Detailed information for compound 324800
Basic information
Technical information
- TDR Targets ID: 324800
- Name: 4-[6-methoxy-7-(2-piperidin-1-ylethoxy)quinaz olin-4-yl]-N-[(5-methylpyrazin-2-yl)methyl]pi perazine-1-carbothioamide
- MW: 536.692 | Formula: C27H36N8O2S
-
H donors: 0
H acceptors: 4
LogP: 2.75
Rotable bonds: 9
Rule of 5 violations (Lipinski): 2 - SMILES: COc1cc2c(cc1OCCN1CCCCC1)ncnc2N1CCN(CC1)/C(=N\Cc1cnc(cn1)C)/S
- InChi: 1S/C27H36N8O2S/c1-20-16-29-21(17-28-20)18-30-27(38)35-10-8-34(9-11-35)26-22-14-24(36-2)25(15-23(22)31-19-32-26)37-13-12-33-6-4-3-5-7-33/h14-17,19H,3-13,18H2,1-2H3,(H,30,38)
- InChiKey: NGRDEBKWNZBWPC-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 4-[6-methoxy-7-[2-(1-piperidyl)ethoxy]quinazolin-4-yl]-N-[(5-methylpyrazin-2-yl)methyl]piperazine-1-carbothioamide
- 4-[6-methoxy-7-[2-(1-piperidyl)ethoxy]-4-quinazolinyl]-N-[(5-methyl-2-pyrazinyl)methyl]-1-piperazinecarbothioamide
- 4-[6-methoxy-7-(2-piperidinoethoxy)quinazolin-4-yl]-N-[(5-methylpyrazin-2-yl)methyl]piperazine-1-carbothioamide
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | platelet-derived growth factor receptor, beta polypeptide | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Echinococcus multilocularis | roundabout 2 | 0.0018 | 0.015 | 0.015 |
| Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.0326 | 0.7224 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.015 | 0.015 |
| Brugia malayi | Dihydrofolate reductase | 0.0447 | 1 | 1 |
| Brugia malayi | thymidylate synthase | 0.0124 | 0.2586 | 0.2586 |
| Loa Loa (eye worm) | hypothetical protein | 0.0018 | 0.015 | 0.015 |
| Brugia malayi | hypothetical protein | 0.0059 | 0.1095 | 0.1095 |
| Schistosoma mansoni | nephrin | 0.0014 | 0.0066 | 0.0066 |
| Loa Loa (eye worm) | dihydrofolate reductase | 0.0447 | 1 | 1 |
| Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.0447 | 1 | 1 |
| Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0326 | 0.7224 | 0.5 |
| Chlamydia trachomatis | dihydrofolate reductase | 0.0447 | 1 | 0.5 |
| Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.0326 | 0.7224 | 0.5 |
| Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0326 | 0.7224 | 0.5 |
| Loa Loa (eye worm) | TK/KIN16 protein kinase | 0.0016 | 0.0107 | 0.0107 |
| Echinococcus multilocularis | dihydrofolate reductase | 0.0447 | 1 | 1 |
| Schistosoma mansoni | cell adhesion molecule | 0.0015 | 0.0084 | 0.0084 |
| Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.0124 | 0.2586 | 0.1674 |
| Echinococcus granulosus | thymidylate synthase | 0.0124 | 0.2586 | 0.2586 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0059 | 0.1095 | 0.5 |
| Echinococcus granulosus | roundabout 2 | 0.0018 | 0.015 | 0.015 |
| Loa Loa (eye worm) | hypothetical protein | 0.0015 | 0.0084 | 0.0084 |
| Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.0326 | 0.7224 | 0.5 |
| Echinococcus granulosus | neurotracting:lsamp:neurotrimin:obcam | 0.0015 | 0.0084 | 0.0084 |
| Echinococcus multilocularis | thymidylate synthase | 0.0124 | 0.2586 | 0.2586 |
| Echinococcus granulosus | twitchin | 0.0014 | 0.0066 | 0.0066 |
| Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.0447 | 1 | 1 |
| Brugia malayi | Immunoglobulin I-set domain containing protein | 0.0016 | 0.0107 | 0.0107 |
| Echinococcus multilocularis | neuroglian | 0.0014 | 0.0066 | 0.0066 |
| Loa Loa (eye worm) | thymidylate synthase | 0.0124 | 0.2586 | 0.2586 |
| Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.0326 | 0.7224 | 1 |
| Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.0124 | 0.2586 | 0.2586 |
| Schistosoma mansoni | dihydrofolate reductase | 0.0447 | 1 | 1 |
| Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.0447 | 1 | 1 |
| Echinococcus granulosus | neuroglian | 0.0014 | 0.0066 | 0.0066 |
| Onchocerca volvulus | 0.0124 | 0.2586 | 0.5 | |
| Echinococcus granulosus | dihydrofolate reductase | 0.0447 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| AUC (ADMET) | = 32.2 ug hr-1 ml-1 | Area under curve was determined in rat by peroral dose of the compound at 30 mg/kg | ChEMBL. | 15341941 |
| AUC (ADMET) | = 832 ug hr-1 ml-1 | Area under curve was determined in monkey by peroral dose of the compound at 10 mg/kg | ChEMBL. | 15341941 |
| AUC (ADMET) | = 1507 ug hr-1 ml-1 | Area under curve was determined in dog by peroral dose of the compound at 8.69 mg/kg | ChEMBL. | 15341941 |
| Cmax (ADMET) | = 235 ug ml-1 | Maximum concentration was determined in monkey by iv/po dose of the compound at 10 mg/kg | ChEMBL. | 15341941 |
| Cmax (ADMET) | = 239 ug ml-1 | Maximum concentration was determined in rat by iv/po dose of the compound at 30 mg/kg | ChEMBL. | 15341941 |
| Cmax (ADMET) | = 297 ug ml-1 | Maximum concentration was determined in dog by iv/po dose of the compound at 8.69 mg/kg | ChEMBL. | 15341941 |
| F (ADMET) | 0 % | Bioavailability in monkey (dose 10 mg/kg i.v./p.o.) | ChEMBL. | 15341941 |
| F (ADMET) | = 13.7 % | Bioavailability in rat (dose 30 mg/kg i.v./p.o.) | ChEMBL. | 15341941 |
| F (ADMET) | = 38.8 % | Percent bioavailability was determined in dog by iv/po dose of the compound at 8.69 mg/kg | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.05 uM | In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasma | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.05 uM | In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells without plasma | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.06 uM | In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells with 45% human plasma | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.06 uM | In vitro inhibition of Platelet derived growth factor receptor beta autophosphorylation in MG-63 cells with 45% human plasma | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.25 uM | Inhibition of Platelet derived growth factor receptor beta autophosphorylation in CHO cells | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.25 uM | Inhibition of Platelet derived growth factor receptor beta autophosphorylation in CHO cells | ChEMBL. | 15341941 |
| IC50 (binding) | = 0.89 uM | Inhibition of PDGFRbeta/c-Kit chimeric receptor autophosphorylation in CHO cells | ChEMBL. | 15341941 |
| IC50 (binding) | > 30 uM | Inhibition of PDGFRbeta/Flt-3 chimeric receptor autophosphorylation in CHO cells | ChEMBL. | 15341941 |
| T1/2 (ADMET) | = 10.8 hr | Plasma half life was determined in dog by iv/po dose of the compound at 8.69 mg/kg | ChEMBL. | 15341941 |
| T1/2 (ADMET) | = 14.1 hr | Plasma half life was determined in rat by iv/po dose of the compound at 30 mg/kg | ChEMBL. | 15341941 |
| T1/2 (ADMET) | = 20.9 hr | Plasma half life was determined in monkey by iv/po dose of the compound at 10 mg/kg | ChEMBL. | 15341941 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL187280
- PubChem: 9828619
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.